Emergency Visits for Oral Anticoagulant Bleeding.

Excludes I n i = 11 cases in which both a DOAC and warfarin were implicated in the ED visit I DOAC i direct-acting oral anticoagulant, I CI i confidence interval *Not shown: I n i = 1 case involving edoxaban-related bleeding †Bleeding manifestations are mutually exclusive and were assigned hierarchically. Among adults aged >= 65 years, DOAC-related bleeding contributed to 11.8% (95% CI, 9.1-14.5%) of ED visits for ADEs from all drugs, while warfarin-related bleeding contributed to 18.6% (95% CI, 15.7-21.5%). Although the rate of DOAC-related bleeding is nominally lower than the rate for warfarin, DOACs are implicated in nearly 40% of estimated visits for oral anticoagulant-related bleeding, with hospitalization rates comparable with those for warfarin. [Extracted from the article]